| To Evaluate the Safety, Pharmacokinetic and Pharmacodynamics of JW0061 in Healthy Volunteers (NCT07514780) | JW Pharmaceutical | 2026-04-13 |
| to Evaluate the Efficacy and Safety of KLH-2109 in Patients With Uterine Fibroids and Menorrhagia (NCT07378098) | JW Pharmaceutical | 2026-02-03 |
| To Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (NCT07374406) | JW Pharmaceutical | 2026-02-02 |
| Glycemic Variability of Combination Therapies in T2DM (NCT07442006) | JW Pharmaceutical | 2025-10-29 |
| To Evaluate the Mass Balance Recovery, Metabolite Profile and Metabolite Identification in Healthy Male Subjects (NCT07036458) | JW Pharmaceutical | 2025-08-22 |
| Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study (NCT07523971) | JW Pharmaceutical | 2025-06-25 |
| Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia (NCT06955104) | JW Pharmaceutical | 2025-04-03 |
| PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers (NCT06665425) | JW Pharmaceutical | 2025-03-24 |
| To Evaluate the Safety and PK Characteristics After Co-administration of JW0104 and C2402 and Administration of JW0105 (NCT06754943) | JW Pharmaceutical | 2025-01-17 |
| To Evaluate the Safety/Tolerability and Pharmacokinetic Characteristics in Healthy Volunteers (NCT06703710) | JW Pharmaceutical | 2025-01-06 |
| Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia (NCT06643130) | JW Pharmaceutical | 2024-12-02 |
| To Evaluate the Safety and PK Characteristics in Healthy Volunteers-JW24107 (NCT06816719) | JW Pharmaceutical | 2024-09-02 |
| PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers (NCT06435442) | JW Pharmaceutical | 2024-06-03 |
| To Evaluate the Pharmacokinetic Characteristics and Safety in Healthy Volunteers (NCT06361277) | JW Pharmaceutical | 2023-11-03 |
| To Evaluate the Safety and Pharmacokinetic Interactions in Healthy Volunteers (NCT06378684) | JW Pharmaceutical | 2023-09-10 |
| To Evaluate the Safety and PK Characteristics in Healthy Volunteers (NCT06355349) | JW Pharmaceutical | 2023-04-28 |
| A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients (NCT05815901) | JW Pharmaceutical | 2023-03-21 |
| To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers (NCT05784155) | JW Pharmaceutical | 2023-03-10 |
| To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM (NCT05814406) | JW Pharmaceutical | 2023-01-12 |
| To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus (NCT05814393) | JW Pharmaceutical | 2023-01-03 |
| Efficacy and Safety of Livalozet® in Hypercholesterolemic Patients With and Without Diabetes (NCT07382778) | JW Pharmaceutical | 2022-10-19 |
| A Trial to Evaluate the Effect of LEO 152020 on the Heart of Healthy People (NCT05508776) | JW Pharmaceutical | 2022-09-16 |
| To Evaluate the PK, PD, Safety and Drug Tolerance in Healthy Volunteers (NCT05433844) | JW Pharmaceutical | 2022-06-02 |
| To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers (NCT05463497) | JW Pharmaceutical | 2022-01-17 |
| Efficacy and Safety of Pitavastatin/Ezetimibe After Switching From Statin Monotherapy to Pitavastatin/Ezetimibe in Patients With Hypercholesterolemia (NCT07445542) | JW Pharmaceutical | 2021-12-18 |
| Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis (NCT05117060) | JW Pharmaceutical | 2021-12-13 |
| A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment (NCT05198778) | JW Pharmaceutical | 2021-11-29 |
| To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers (NCT05351840) | JW Pharmaceutical | 2020-11-02 |
| A Trial to Evaluate the Effect of Food on LEO 152020 (NCT04203836) | JW Pharmaceutical | 2020-01-09 |
| The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors (NCT04805801) | JW Pharmaceutical | 2019-08-28 |
| To Evaluate the Efficacy and Safety in Patients With Primary Hypercholesterolemia (NCT04584736) | JW Pharmaceutical | 2019-06-11 |
| Single and Multiple Ascending Dose Study of JW1601 for Healthy Volunteers (NCT04018170) | JW Pharmaceutical | 2019-02-15 |
| Registry Study of ID & IDA in Korean Patients With Heart Failure (NCT04812873) | JW Pharmaceutical | 2019-01-30 |
| Study of of URC102 to Assess the Efficacy and Safety in Gout Patients (NCT04804111) | JW Pharmaceutical | 2019-01-21 |
| A Study to Evaluate Efficacy and Safety of JTZ-951 Compared to Darbepoetin Alfa in Korean Renal Anemia Patients Receiving Hemodialysis. (NCT04027517) | JW Pharmaceutical | 2019-01-15 |
| MAGE of Anagliptin Compared With Sitagliptin With Type 2 Diabetes Mellitus (NCT04810507) | JW Pharmaceutical | 2018-11-09 |
| The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment (NCT04270344) | JW Pharmaceutical | 2018-07-01 |